Nova Eye Medical (ASX:EYE) Inventories, Finished Goods: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:EYE Nova Eye Medical Ltd ASX:EYE
51 GF Score
Price A$0.14
GF Value A$0.19
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Nova Eye Medical Inventories, Finished Goods?

Nova Eye Medical ASX:EYE +17.39% 51 Inventories, Finished Goods is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:EYE with a GF Score™ of 51/100 and a GF Value™ of A$0.19 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Nova Eye Medical's quarterly finished goods increased from Dec. 2024 (A$0.00 Mil) to Jun. 2025 (A$3.20 Mil) but then declined from Jun. 2025 (A$3.20 Mil) to Dec. 2025 (A$0.00 Mil).

Nova Eye Medical's annual finished goods increased from Jun. 2023 (A$2.64 Mil) to Jun. 2024 (A$2.93 Mil) and increased from Jun. 2024 (A$2.93 Mil) to Jun. 2025 (A$3.20 Mil).

Nova Eye Medical Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Nova Eye Medical's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nova Eye Medical Inventories, Finished Goods Chart

Nova Eye Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.08 2.14 2.64 2.93 3.20

Nova Eye Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2.93 0.00 3.20 0.00
ASX:EYE
51GF Score
Nova Eye Medical Ltd ASX:EYE
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nova Eye Medical Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of A$0.00 Mil mean?
Nova Eye Medical (ASX:EYE) has a Inventories, Finished Goods of A$0.00 Mil as of Dec. 2025. Finished goods are inventory items that are complete and ready to be sold. View historical data on Nova Eye Medical and its competitors.
Is Nova Eye Medical's Inventories, Finished Goods too high?
Nova Eye Medical's current Inventories, Finished Goods is A$0.00 Mil. Overall, Nova Eye Medical has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's Inventories, Finished Goods compare to ABT and SYK?
Nova Eye Medical's Inventories, Finished Goods of A$0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Medical Devices & Instruments company?
A good Inventories, Finished Goods depends on the Medical Devices & Instruments industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Nova Eye Medical and its competitors. Nova Eye Medical's current Inventories, Finished Goods is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Based on GuruFocus' analysis, Nova Eye Medical (ASX:EYE) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.19, compared to a current price of A$0.14 — trading 28.9% below its estimated fair value. The current Inventories, Finished Goods is A$0.00 Mil. Nova Eye Medical's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Nova Eye Medical (ASX:EYE), the current Inventories, Finished Goods is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nova Eye Medical (ASX:EYE) Overvalued in 2026?

Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued. The current stock price of A$0.14 is trading 28.9% below its estimated GF Value™ of A$0.19. GuruFocus considers Nova Eye Medical to be Modestly Undervalued.

Key valuation signals for ASX:EYE:

  • Inventories, Finished Goods: A$0.00 Mil
  • GF Value™: A$0.19 vs. price of A$0.14 (28.9% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the ASX:EYE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nova Eye Medical Business Description

Address 107 Rundle Street, Kent Town, Adelaide, SA, AUS, 5067
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
51GF Score

Get the complete analysis for ASX:EYE

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.14
Price
A$0.19
GF Value